Dr. Patrick Nachman Answers Common Questions about Rituximab Treatment in New Chair's Corner Podcast
What should patients know about treatment with rituximab for ANCA vasculitis? What do physicians consider when starting a patient on this medication? Dr. Patrick Nachman and Dr. Ron Falk explain these details in a new episode of Chair's Corner. Dr. Patrick Nachman is the Covington Distinguished Professor of Medicine in the Division of Nephrology and Hypertension at UNC, and he also serves as the Deputy Director for the UNC Kidney Center.
Researchers Discuss Challenges, Successes of HIV Cure Research in Science
A better understanding of HIV latency is the key to eradicating the virus researchers at the University of North Carolina and partner institutions write in a perspective in the journal Science. Worldwide, 37 million people are living with HIV. A cure has proved elusive due to viral latency – a period when the virus remains alive, but dormant in body thereby eluding the immune system.
Study Led by Dr. Myron Cohen Proves that HIV Treatment will Prevent Infection
Anti-HIV medications suppress the viral load of people living with HIV and provide durable protection against heterosexual transmission, a study led by the University of North Carolina at Chapel Hill found. Researchers found a 93 percent reduction of HIV transmission when the HIV-infected person started antiretroviral therapy or ART at a higher CD4 cell count. The groundbreaking final results of the HIV Prevention Trials Network (HPTN) 052 study were published in the New England Journal of Medicine.